1588. Activity of Imipenem/Relebactam Against Clinical Isolates of P. aeruginosa and K. pneumoniae Collected in Asia/Pacific Countries – SMART 2016-2018

BACKGROUND: Relebactam (REL) inhibits class A and C β-lactamases and was approved in the USA in combination with imipenem (IMI) and cilastatin for the treatment of complicated intraabdominal and urinary tract infections. We evaluated the activity of IMI/REL against clinical isolates collected in Asi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lob, Sibylle, Kazmierczak, Krystyna, Chen, Wei-Ting, Khan, Tsz Kin, Young, Katherine, Motyl, Mary, Sahm, Daniel F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778010/
http://dx.doi.org/10.1093/ofid/ofaa439.1768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778010/
http://dx.doi.org/10.1093/ofid/ofaa439.1768

Ejemplares similares